MIM
LFCR icon

MetLife Investment Management’s Lifecore Biomedical LFCR Stock Holding History

MetLife Investment Management’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,660
Closed -$87.2K – 2814
2025
Q4 		$87.2K Sell
10,660
-5,835
-35% -$43.2K ﹤0.01% 2651
2025
Q3 		$121K Buy
16,495
+1,277
+8% +$9.66K ﹤0.01% 2561
2025
Q2 		$124K Buy
15,218
+4,431
+41% +$29.9K ﹤0.01% 2434
2025
Q1 		$75.9K Sell
10,787
-3,726
-26% -$23.2K ﹤0.01% 2627
2024
Q4 		$108K Buy
+14,513
New +$92.7K ﹤0.01% 2586
2023
Q2 		– Sell
-7,378
Closed -$27.9K – 2968
2023
Q1 		$27.9K Sell
7,378
-7,495
-50% -$41.8K ﹤0.01% 2761
2022
Q4 		$96.4K Hold
14,873
– – ﹤0.01% 2608
2022
Q3 		$132K Buy
14,873
+3,034
+26% +$30.9K ﹤0.01% 2540
2022
Q2 		$118K Sell
11,839
-3,171
-21% -$31.4K ﹤0.01% 2645
2022
Q1 		$174K Buy
15,010
+12,372
+469% +$138K ﹤0.01% 2443
2021
Q4 		$29.3K Sell
2,638
-7,356
-74% -$71.4K ﹤0.01% 2480
2021
Q3 		$92.1K Buy
+9,994
New +$109K ﹤0.01% 2473
2021
Q1 		– Sell
-12,181
Closed -$132K – 2326
2020
Q4 		$132K Buy
12,181
+78
+0.6% +$806 ﹤0.01% 2176
2020
Q3 		$118K Hold
12,103
– – ﹤0.01% 2143
2020
Q2 		$96.3K Hold
12,103
– – ﹤0.01% 2267
2020
Q1 		$105K Hold
12,103
– – ﹤0.01% 2047
2019
Q4 		$137K Buy
12,103
+6,649
+122% +$70.8K ﹤0.01% 2176
2019
Q3 		$59.3K Sell
5,454
-8,556
-61% -$93.1K ﹤0.01% 2323
2019
Q2 		$131K Hold
14,010
– – ﹤0.01% 2256
2019
Q1 		$172K Hold
14,010
– – ﹤0.01% 2053
2018
Q4 		$166K Hold
14,010
– – ﹤0.01% 2010
2018
Q3 		$202K Hold
14,010
– – ﹤0.01% 2075
2018
Q2 		$209K Hold
14,010
– – ﹤0.01% 1900
2018
Q1 		$183K Hold
14,010
– – ﹤0.01% 1936
2017
Q4 		$177K Buy
+14,010
New +$177K ﹤0.01% 1992

Other funds holding LFCR

2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
3C
325 Capital New York $274M AUM 49.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GC
Grizzlyrock Capital Chicago, Illinois $126M AUM 11.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MetLife Investment Management's LFCR Position: Q1 2026 in Review

MetLife Investment Management sold out of Lifecore Biomedical (LFCR) in Q1 2026, closing a stake of 10,660 shares — an estimated $87.2K sold.

MetLife Investment Management first reported a position in LFCR in Q4 2017 and held it in 25 quarters. The position peaked at $209K in Q2 2018. 105 funds tracked by Wall St. Rank hold LFCR as of Q1 2026.

  • MetLife Investment Management reported no remaining Lifecore Biomedical position as of Q1 2026 after selling out during the quarter.
  • MetLife Investment Management sold 10,660 Lifecore Biomedical shares in Q1 2026, an estimated $87.2K.
  • MetLife Investment Management first reported a position in Lifecore Biomedical in Q4 2017 and held it in 25 quarters.
  • MetLife Investment Management's Lifecore Biomedical position peaked at $209K in Q2 2018.
  • 105 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.